ArticleJournal of molecular histology2025
Artemisinin effects on Gastrointestinal tissues in Candida albicans-infected mice: histological and functional evaluation.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCandida albicans represents one of the most prevalent species of fungi in the human mycobiome. which colonize the multiple sites of the body, like the oral cavity. This study aimed to investigate the antifungal and tissue-protective effects of artemisinin against Candida albicans in mouse models.
methodsWe collected 120 oral swabs from patients and healthy individuals. Chromogenic Candida differential agar was applied to diagnose Candida isolates. The Vitek2 system is used to confirm Candida spp. diagnosis for patient samples. Moreover, in vitro and in vivo experimentation were applied to evaluate Artemisinin's effects on Candida albicans and animal tissue.
resultsThe results indicate that the number of positive samples for Candida albicans growth among patients was 54 (90%), compared to healthy individuals that was recorded 17 (28.3%). The distribution results of those infected with oral candidiasis according to age groups showed that the age group older than 50 years accounted for 20%. Regarding the effect of Artemisinin on C. albicans, it was shown that after treating C. albicans with Artemisinin (0.2 mg/gram) for 3 h, the number of C. albicans decreased and affected the morphology of hyphae and growth of Candida compared with Fluconazole (0.53 mg/20 g) and the control. The results of the survival rate were lowest in the mice group treated with (Neoral + Fungi + artemisinin + fluconazole). While the survival rate was highest in mice groups treated with (Neoral), (Fungi), (Neoral + Fungi + fluconazole), (Neoral + Fungi + Artemisinin), (Fungi + fluconazole), (Fungi + Artemisinin), (Fungi + fluconazole + Artemisinin), respectively. These groups recorded less mortality. Concerning the histological examination of the tongue in infected mice, it was observed that there was epithelial ulceration with infiltration of inflammatory cells and epithelial sloughing, along with degeneration and necrosis of gastric glandular cells in the stomach. Additionally, the duodenum tissue showed mild inflammation of the intestinal mucosa, with thickening of the villi due to epithelial hyperplasia and infiltration. Meanwhile, mice treated with Artemisinin displayed normal tissue appearance.
conclusionArtemisinin demonstrated significant antifungal effectiveness against Candida albicans in both in vitro and in vivo. It diminished fungal load, impeded hyphal development, and preserved gastrointestinal tissue integrity in infected mice.
Indexed as
Identifiers
41152651What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.